Results 41 to 50 of about 6,183,390 (300)
BMC Public Health, 2022 Background Antigen tests for SARS-CoV-2 offer advantages over nucleic acid amplification tests (NAATs, such as RT-PCR), including lower cost and rapid return of results, but show reduced sensitivity.
Phillip P. Salvatore +6 more
doaj +1 more source
Journal of Clinical Medicine, 2021 Diabetes mellitus (DM) is one of the most common comorbid conditions in persons with COVID-19 and a risk factor for poor prognosis. The reasons why COVID-19 is more severe in persons with DM are currently unknown although the scarce data available on patients with DM hospitalized because of COVID-19 show that glycemic control is inadequate.
Virginia Bellido, Antonio Pérez
openaire +4 more sources
Inflammation and Regeneration, 2020 Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in Wuhan, China, and has spread globally to most countries. In Japan, the first COVID-19 patient was identified on January 15, 2020.
Tokio Hoshina +8 more
doaj +1 more source
BMC Public Health, 2021 Background Shielding of high-risk groups from coronavirus disease (COVID-19) has been suggested as a realistic alternative to severe movement restrictions during the COVID-19 epidemic in low-income countries. The intervention entails the establishment of
Nada Abdelmagid +6 more
doaj +1 more source
F1000Research, 2022 Background: Following the surge of coronavirus disease 2019 (COVID-19) cases in the epicenter of East Java Province, this study aimed to determine the clinical characteristics of patients with COVID-19 at one of the emergency field hospitals in Indonesia.
Ahmad Maulana Ifan Akbas +9 more
doaj +1 more source
Procalcitonin as a Predictive Factor for the Clinical Outcome of Patients with Coronavirus Disease 2019 [PDF]
Journal of Acute Care Surgery, 2022 Purpose The coronavirus disease 2019 (COVID-19) pandemic continues. It has been reported that patients with bacterial coinfection have a higher mortality rate than patients without coinfection.
Sungho Lee +5 more
doaj +1 more source
A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19
, 2021 BACKGROUND: Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody) may attenuate the inflammatory response in Covid-19. METHODS: We performed an adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial of intravenous sarilumab 200 ...
DiCioccio, A. Thomas +39 more
core +1 more source
COVID-19 or not COVID-19? Compared characteristics of patients hospitalized for suspected COVID-19 [PDF]
European Journal of Clinical Microbiology & Infectious Diseases, 2021 During an epidemic period, we compared patients hospitalized for initial suspicion of COVID-19 but for whom an alternative diagnosis was finally retained (n = 152) with those who had COVID-19 (n = 222). Most common diagnoses were another infectious disease and heart failure. COVID-19-negative patients were more often active smokers had less often cough,
Thomas Rogier +20 more
openaire +2 more sources
Emergence and expansion of highly infectious spike protein D614G mutant SARS-CoV-2 in central India
Scientific Reports, 2021 COVID-19 has emerged as global pandemic with largest damage to the public health, economy and human psyche.The genome sequence data obtained during the ongoing pandemic are valuable to understand the virus evolutionary patterns and spread across the ...
Shashi Sharma +18 more
doaj +1 more source